Addex Therapeutics Ltd ADXN
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 300.00 | 37.20K | -- |
| Total Other Revenue | 12.60K | 9.80K | 19.50K | 24.80K | 79.00K |
| Total Revenue | 12.60K | 9.80K | 19.80K | 62.00K | 79.00K |
| Cost of Revenue | 48.10K | 46.10K | 66.10K | 285.40K | 173.60K |
| Gross Profit | -35.50K | -36.30K | -46.30K | -223.40K | -94.60K |
| SG&A Expenses | 781.30K | 575.90K | 929.10K | 646.90K | 579.80K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 829.40K | 622.00K | 995.20K | 932.30K | 753.40K |
| Operating Income | -816.80K | -612.20K | -975.40K | -870.30K | -674.40K |
| Income Before Tax | -2.21M | -2.18M | -2.30M | -1.97M | -1.64M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.21M | -2.18M | -2.30M | -1.97M | -1.64M |
| Earnings from Discontinued Operations | -- | -- | -4.30K | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.21M | -2.18M | -2.30M | -1.97M | -1.64M |
| EBIT | -816.80K | -612.20K | -975.40K | -870.30K | -674.40K |
| EBITDA | -816.70K | -612.00K | -975.30K | -870.10K | -672.00K |
| EPS Basic | -0.02 | -0.02 | -0.02 | -0.02 | -0.02 |
| Normalized Basic EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| EPS Diluted | -0.02 | -0.02 | -0.02 | -0.02 | -0.02 |
| Normalized Diluted EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Average Basic Shares Outstanding | 122.59M | 118.53M | 117.88M | 112.68M | 98.35M |
| Average Diluted Shares Outstanding | 122.59M | 118.53M | 117.88M | 112.68M | 98.35M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |